Call to expand statin use in primary prevention

STATIN use in primary prevention should be broadened to include people at intermediate risk of cardiovascular disease, according to trial findings presented over the weekend.

The first of a series of three studies found a 24% lower incidence of a major cardiovascular event in moderate-risk men and women randomised to rosuvastatin, compared with placebo, with a mean follow-up of almost six years.

Statin therapy in these patients was &ldquo